MyPeptideMatch
Semaglutide vs. Tirzepatide Side Effects: A Direct Comparison (2026)
Both semaglutide and tirzepatide share GLP-1-mediated gastrointestinal side effects as their most common adverse events. Tirzepatide adds GIP receptor activation, which may slightly modify the side effect profile — here is what the data shows.
Side Effects Comparison Table
| Side Effect | Semaglutide | Tirzepatide | Notes |
|---|---|---|---|
| Nausea | 20–44% | 17–31% | Most common; peaks early in titration |
| Vomiting | 9–24% | 6–16% | Related to gastric emptying slowdown |
| Diarrhea | 12–30% | 13–22% | Common in early weeks |
| Constipation | 14–24% | 11–20% | Especially after dose escalation |
| Abdominal pain | 6–10% | 5–9% | Often improves with slower titration |
| Fatigue | 11–14% | 8–13% | Temporary; often first 4–8 weeks |
| Injection site reaction | 3–5% | 3–7% | Local redness, itching |
| Pancreatitis | <0.3% | <0.3% | Rare but serious; seek immediate care |
| Gallbladder disease | ~2% | ~2% | Cholelithiasis risk elevated |
| Hair loss (telogen effluvium) | Reported | Reported | Related to rapid weight loss; typically temporary |
Data sourced from STEP (semaglutide) and SURMOUNT (tirzepatide) Phase III trial programs.
Do Semaglutide and Tirzepatide Have the Same Side Effects?
Largely yes, because both drugs activate GLP-1 receptors, which slow gastric emptying and cause GI effects. The main potential difference is that tirzepatide's additional GIP receptor activation may:
- Reduce nausea severity slightly (GIP has been proposed to be GI-protective in some models)
- Improve insulin secretion with less nausea than GLP-1 stimulation alone
Clinical reality: The difference in GI side effect rates between semaglutide and tirzepatide is modest in trial data and may not be clinically meaningful for most patients. Individual variation is more significant than the drug-class difference.
Serious Side Effects (Both Drugs)
Pancreatitis
Both drugs carry a warning for pancreatitis. Risk appears low (<0.3% in trials) but real. Symptoms: severe abdominal pain radiating to the back, nausea, vomiting. Seek immediate medical care if these occur.
Thyroid C-Cell Tumors
Both drugs carry an FDA black box warning based on rodent studies showing thyroid C-cell tumors. This has not been confirmed in human studies. Both are contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.
Gallbladder Problems
Rapid weight loss increases gallstone risk regardless of medication. Both GLP-1 drugs further reduce gallbladder motility. Cholelithiasis and cholecystitis are reported at ~2% in trials.
Kidney Injury
Severe nausea/vomiting leading to dehydration can cause acute kidney injury. Maintain adequate hydration, particularly early in treatment.
Managing Side Effects
The most effective strategy is slow titration:
- Semaglutide: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg over 16–20 weeks
- Tirzepatide: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg over 20–24 weeks
Other strategies:
- Take injections at bedtime — nausea is less bothersome during sleep
- Eat smaller, lower-fat meals
- Avoid high-fat or spicy food during dose escalation
- Stay hydrated
- Ask your physician about temporary dose reduction if GI effects are severe
Which Drug Has Worse Side Effects?
Neither clearly has a worse side effect profile. Tirzepatide trials showed modestly lower nausea rates than semaglutide at comparable doses, but head-to-head comparison suggests broadly similar tolerability. Tirzepatide produces more weight loss, which may result in more hair loss (telogen effluvium) due to greater caloric restriction — though this is temporary.
Frequently Asked Questions
Which has worse side effects, semaglutide or tirzepatide?
Neither is dramatically worse. Both cause GLP-1-mediated GI side effects. Tirzepatide trial data shows slightly lower nausea rates; semaglutide has a longer post-market safety record. Individual experience varies considerably.
Does tirzepatide cause less nausea than semaglutide?
Tirzepatide trials showed slightly lower rates of nausea vs. semaglutide in some analyses (attributed to GIP co-agonism). In practice, the difference is modest and not guaranteed for every patient.
Do side effects go away?
Yes — for most patients, GI side effects are most pronounced in the first 4–8 weeks of starting or increasing a dose, and diminish significantly during maintenance dosing. For a minority of patients, side effects are persistent enough to require dose adjustment or discontinuation.
Can you take anti-nausea medication with semaglutide or tirzepatide?
Yes, with physician guidance. Ondansetron (Zofran) is commonly used for nausea management. Do not take anti-nausea medications long-term without discussing with your provider.
For informational purposes only. Both medications require physician prescription. Consult your healthcare provider for personalized guidance.
